The goal of this randomized clinical trial is to test the topical drug clascoterone in patients with pilonidal disease, which is a common, benign skin condition of the gluteal cleft. The main questions it aims to answer are:
* Does clascoterone improve the severity of pilonidal disease as scored by a physician?
* Does clascoterone improve patient symptoms due to pilonidal disease?
* Does clascoterone improve the inflammation seen under the microscope in pilonidal disease removed at surgery Participants will apply clascoterone or a placebo cream to the diseased area for 3 months. They will be assessed every 4 weeks for disease severity assessed by a physician viewing patient photos and a symptom-based survey.
Researchers will compare participants who received clascoterone treatment to those who received placebo.

开始日期2025-01-10

申办/合作机构

University of Pennsylvania

NCT06454708

/ Completed临床1期

An Open Phase I Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Single Dose and Repeat Dose Topical Administrations of Clascoterone Cream, 1% in Healthy Chinese Adult Subjects

The primary objective of this study is to determine the pharmacokinetics (PK) of Clascoterone Cream, 1% after single dose and repeat dose topical administrations in healthy Chinese adult subjects.

开始日期2024-08-01

申办/合作机构

浙江三生蔓迪药业有限公司

100 项与克拉司酮相关的临床结果

登录后查看更多信息

100 项与克拉司酮相关的转化医学

登录后查看更多信息

100 项与克拉司酮相关的专利（医药）

登录后查看更多信息

项与克拉司酮相关的文献（医药）

2025-12-31·JOURNAL OF DERMATOLOGICAL TREATMENT

Efficacy of oral isotretinoin monotherapy compared to combination isotretinoin and topical clascoterone for severe acne vulgaris: a multi-center retrospective study

Article

作者: Abu-Hilal, Mohannad ; Cy, Ajith ; Bawazir, Mohamed ; Metko, Dea ; Xiong, Grace ; Choi, UYeong ; Pathayappura, Smitha

INTRODUCTION:

Severe nodular acne causes significant psychological distress and reduces quality of life. Clascoterone 1% cream, a novel anti-androgen with a favorable safety profile, may enhance the efficacy of oral isotretinoin, the gold-standard therapy for severe acne. This study compared isotretinoin monotherapy with isotretinoin plus topical clascoterone 1% cream.

METHODS:

Since June 2023, patients with severe/nodular acne at university-affiliated dermatology clinics were treated with isotretinoin, alone or combined with clascoterone 1% cream twice daily. In December 2024, records were retrospectively reviewed. The analysis included patients aged ≥12 years with severe/nodular acne who received isotretinoin (0.5-0.8 mg/kg/day) with or without clascoterone 1% cream for ≥24 weeks. Outcomes included facial lesion count, Investigator's Global Assessment (IGA), and facial xerosis at week 24.

RESULTS:

Eighty-two patients (44 monotherapy; 38 combination therapy) were included. Both groups showed significant reduction in facial lesion count (p < 0.001), but between-group differences were not significant. More patients in the combination group achieved IGA 0/1 (92.1% vs. 72.7%; p < 0.05). Xerosis rates were lower in the combination group (84% vs. 91%) but not statistically significant.

CONCLUSION:

Clascoterone 1% cream may enhance isotretinoin efficacy without worsening adverse effects, offering a promising approach for severe/nodular acne. Further studies are needed to confirm long-term benefits.

2025-09-01·Dermatology and Therapy

Reduction in Facial Sebum Production Following Treatment with Clascoterone Cream 1% in Patients with Acne Vulgaris: 12-Week Interim Analysis

Article

作者: Kyeremateng, Kizito ; Squittieri, Nicholas ; Draelos, Zoe D

INTRODUCTION:

In vitro, clascoterone inhibits androgen-induced sebum production-a key driver of acne pathogenesis-although the exact mechanism of action of clascoterone for the treatment of acne is unknown. This study evaluated reductions in casual sebum production following 12 weeks of clascoterone cream 1% treatment in patients with acne.

METHODS:

Patients ≥ 12 years old with mild-to-moderate acne applied clascoterone cream 1% twice daily for 12 weeks. The primary endpoint was the reduction in casual sebum measurements at Week 12. Additional endpoints included Investigator's Global Assessment (IGA) score, inflammatory and noninflammatory lesion counts (ILC and NILC), and tolerability. Data were analyzed using Student's t-test and Wilcoxon signed-rank test.

RESULTS:

Forty patients with a mean age of 20.9 years were enrolled, all of whom completed Week 12. Significant percentage reductions from baseline were observed in sebum measurements (27%), ILC (54%), and NILC (34%; all p < 0.001), and patients achieved a 29% reduction in IGA score. No tolerability or safety issues were identified during the 12-week interim analysis period.

CONCLUSION:

Clascoterone cream 1% led to significant reductions in sebum measurements with improvements in acne severity and was well tolerated.

TRIAL REGISTRATION:

ClinicalTrials.gov identifier, NCT06415279.

2025-07-01·CANADIAN FAMILY PHYSICIAN

Update to acne vulgaris treatment for Canadian practice

Review

作者: Keow, Samantha ; Xiong, Grace ; Abu-Hilal, Mohannad

OBJECTIVE:

To provide updates and apply the new 2024 American Academy of Dermatology (AAD) guidelines of care for the management of acne vulgaris (AV) to Canadian practice and summarize current evidence-based practices, treatments, and emerging trends in acne management.

QUALITY OF EVIDENCE:

As per published guidelines, MEDLINE and Embase databases were searched for literature on the effectiveness and safety of available and approved treatments for AV in patients aged 9 and older in the United States. Studies meeting patient or population, intervention, comparison, and outcomes (PICO) criteria were extracted, and quality was assessed using the Cochrane Risk of Bias tool. A Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to classify evidence certainty as high, moderate, low, or very low, and categorize recommendations as strong or conditional. The federal Drug and Health Product Register was then searched for approved and marketed treatments currently available in Canada.

MAIN MESSAGE:

Topical therapies such as benzoyl peroxide, antibiotics, and fixed-dose combinations received strong recommendations, while retinoids, clascoterone, salicylic acid, and azelaic acid received conditional recommendations. Topical minocycline is not yet available in Canada. Oral therapies such as doxycycline and isotretinoin received strong recommendations, while minocycline, combined oral contraceptives, and spironolactone received condition recommendations. Isotretinoin remains the criterion standard for treating severe acne and scarring; frequent monitoring is unnecessary for most patients receiving oral isotretinoin, and it is unlikely to be associated with neuropsychiatric disorders or inflammatory bowel disease. Intralesional corticosteroids were also strongly recommended for acne at high risk of scarring. Additional consideration must be given to pregnant individuals, people with skin of colour, and those undergoing gender-affirming therapy.

CONCLUSION:

The 2024 AAD guidelines provide a valuable framework for Canadian management of AV. Mild cases are managed with topical treatments, while moderate to severe cases often require oral medication. Antibiotic monotherapy is discouraged; combination with benzoyl peroxide may mitigate antibiotic resistance. Treatments using multiple modalities and mechanisms of action are recommended.

项与克拉司酮相关的新闻（医药）

2025-09-19

·FiercePharma

Novo's once-weekly combo drug for Type 2 diabetes scores EU endorsement

Europe's Committee for Medicinal Products for Human Use has recommended several products for approval, including Novo Nordisk's diabetes drug Kyinsu and Bayer's menopause treatment Lynkuet. A year after Novo Nordisk surrendered its pursuit of an approval in the U.S. for IcoSema as a treatment for Type 2 diabetes, the Danish company has scored a recommendation for the combination drug in Europe.The Committee for Medicinal Products for Human Use (CHMP) has given a thumbs-up to once-weekly Kyinsu, as it is known in Europe, to treat patients with Type 2 diabetes who can’t get sufficient control of their blood sugar with basal insulin or glucagon-like peptide 1 (GLP-1) receptor agonists.Kyinsu combines once-weekly insulin Awiqli (icodec) with GLP-1 Type 2 diabetes treatment Ozempic (semaglutide).In July of last year, the FDA rejected icodec as a treatment for Type 1 and Type 2 diabetes, citing its “manufacturing process.” The U.S. regulator also was swayed by a panel of experts who voted 7-4 against recommending it for approval in its Type 1 diabetes indication because of concerns about its potential to trigger episodes of low blood sugar.The FDA’s complete response letter came three months after the European Medicines Agency (EMA) granted marketing authorization to Awiqli as a treatment for Type 1 and Type 2 diabetes, following a positive opinion from CHMP.Drug endorsements for Bayer, Merck and more The CHMP also recommended Bayer’s Lynkuet (elinzanetant) for approval to treat moderate-to-severe hot flashes or night sweats that accompany menopause.In July, the UK and Canada approved the dual-action neurokinin, which targets the NK-3 and NK-1 receptors. The FDA also was expected to sign off on Lynkuet in July, but the regulator pushed the decision date forward by three months to Oct. 26.With nods in the U.S. and Europe, Bayer would join Astellas as the second company with a hormone-free treatment for patients with moderate to severe hot flashes. Veozah was the first neurokinin 3 (NK-3) receptor antagonist approved in the indication and has drawn a peak sales potential projection of $3.6 billion from the company.The CHMP also issued a positive opinion on Merck’s monoclonal antibody Enflonsia to prevent lower respiratory tract disease associated with respiratory syncytial virus (RSV). The shot, which is for infants, was approved by the FDA in June and enters the market as a challenger to AstraZeneca and GSK’s blockbuster Beyfortus.Also making the grade with the CHMP experts was Johnson & Johnson’s Imaavy as a treatment for generalized myasthenia gravis (gMG). The European recommendation comes five months after the FDA endorsed Imaavy in the same indication.After a re-examination, the CHMP has recommended granting marketing authorization for Cosmo Pharmaceuticals’ topical acne treatment Winlevi. The nod comes five months after the committee gave it a thumbs-down. Label expansions The CHMP has endorsed Amgen’s Uplizna as a treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition that can present in multiple organs and cause fibrosis and permanent organ damage, with or without symptoms. The FDA signed off on Uplizna for the disorder in April, five years after the drug hit the market as a treatment for neuromyelitis optica spectrum disorder (NMOSD).Collecting two positive opinions from the CHMP was Merck’s cancer powerhouse Keytruda. One of the nods is to recommend approval of a subcutaneous route of administration for Keytruda and its associated formulation tweak. The recommendation applies to all approved adult indications in Europe. The FDA is expected to decide on the SC version of Keytruda next week.The other thumbs-up is for Keytruda as a treatment for locally advanced head and neck squamous cell carcinoma and comes three months after the FDA signed off on the PD-1 inhibitor in the indication.The CHMP has given a nod to Regeneron and Sanofi’s Dupixent as a treatment for the hives condition, chronic spontaneous urticaria (CSU). The FDA approved Dupixent in the indication in April of this year, making it the first new medicine for CSU in more than a decade.Hipra Human Health has secured a CHMP recommendation for Bimervax as a booster to prevent COVID-19 in those 12 and older who have previously received an mRNA COVID-19 shot. The EU originally approved the booster in 2023 for those aged 16 and older.Also making the grade with CHMP were AstraZeneca and Amgen's Tezspire as a treatment for chronic rhinosinusitis with nasal polyps. AZ's Koselugo got a thumbs-up for symptomatic, inoperable plexiform neurofibromas in adult and pediatric patients with neurofibromatosis type 1 aged 3 years and older.

上市批准

2025-08-12

·开拓药业

GT20029凝胶治疗痤疮中国II期临床试验达到主要终点

北京时间2025年8月12日，开拓药业（股票代码：9939.HK），宣布其自主研发的新型靶向雄激素受体（AR）的蛋白降解嵌合体（PROTAC）化合物GT20029治疗痤疮的中国II期临床试验读出顶线数据。数据显示，该项II期临床试验成功达到主要研究终点，结果具有统计学显著性及临床意义，且有效性、安全性和药代动力学特征均表现出色，并确定III期临床试验的推荐剂量为0.5%。详细的顶线结果资料未来预计在学术期刊或学术会议上予以公布。该项II期临床试验是一项多中心、随机、双盲、安慰剂对照的研究，选用GT20029 0.5%每天一次（QD）和1.0% QD作为研究药物给药剂量，用以评估GT20029治疗痤疮的有效性、安全性和药代动力学特征。该项II期临床试验在全国10家中心开展，由复旦大学附属华山医院的项蕾红教授担任主要研究者。分析结果显示：有效性方面。与安慰剂组相比，在总病变计数（除外结节）类别中，0.5% QD组和1.0% QD组的P值分别为0.01和0.05。在非炎性皮损计数较基线数值变化的百分比分析中，与安慰剂相比，0.5% QD组和1.0% QD组的P值分别为0.14和0.09；在炎性皮损计数较基线数值变化的百分比分析中，与安慰剂相比，0.5% QD组和1.0% QD组的P值均小于0.01。与安慰剂组相比，治疗成功率（根据研究者整体评估评分，把IGA评分下降到0-1分且下降等级≥2级记为成功），0.5% QD组和1.0% QD组的P值分别为0.03和0.15。安全性方面。GT20029凝胶在临床试验显示出令人满意的安全性和耐受性，整体不良事件发生率低。0.5% QD组和1.0% QD组的与药物相关的不良事件发生率相当，且均低于安慰剂组，严重程度均为轻度。 GT20029作为我们核心产品之一，是本公司基于自有的PROTAC平台自主开发，有潜力成为雄激素性脱发及痤疮的新一代治疗药物。其自开发以来始终保持领先地位，是全球范围内首款完成II期临床试验的外用PROTAC化合物。我们正在制定GT20029治疗痤疮的未来临床策略，包括开启治疗痤疮中国III期临床试验，进一步扩大在外用PROTAC领域的先发优势。 Winlevi®（clascoterone 1%，乳膏剂）是美国食品和药物管理局（FDA）近40年来批准的首款具有新作用机制（MOA）的痤疮药物，用于治疗12岁及以上患者的痤疮。根据Cosmo Pharmaceuticals N.V. 的公开披露，Winlevi® 已经成为美国市场处方量最多的品牌外用痤疮药物，自其上市以来，Winlevi® 已获超17900名医师开具逾130万张处方。同AR靶点的痤疮药物获批，表明通过阻断/降解AR信号通路来治疗痤疮的作用机制已得到验证。GT20029有望为皮肤科医生和患者提供一种创新、安全且有效的新治疗选择。关于开拓药业开拓药业成立于2009年，专注发展潜在“first-in-class”和“best-in-class”创新药物和功效性化妆品的研发及产业化，致力成为行业内的领军企业，并打造由外用创新药物研发业务、B2B功效性化妆品原料业务和B2C功效性化妆品产品业务共同组成的「三驾马车」商业模式。公司经过多年的发展，以皮科领域和肿瘤相关疾病为核心，研发多通道产品组合，产品覆盖全球高发病率疾病，并外延至功效性化妆品领域，可满足全球范围内的皮科临床需求及化妆品消费者需求。开拓药业前瞻性布局了包含小分子创新药及生物创新药的多元化产品管线，包括5款正在开展临床研究的产品以及多个正在进行临床前研究的项目。公司在全球拥有超百项已获得及申请中的专利。2020年5月22日，开拓药业正式在香港联合交易所有限公司主板挂牌上市，股票代码：9939.HK。欢迎访问公司网站：www.kintor.com.cn

临床2期蛋白降解靶向嵌合体临床3期临床结果临床1期

2025-08-12

·开拓药业

GT20029 China Phase II Trial For Acne Reached Primary Endpoint

Suzhou, 12 August, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the Phase II Clinical Trial of its in-house developed androgen receptor (AR) proteolysis targeting chimera (PROTAC) compound GT20029 for the treatment of acne has read out the topline results. Results indicated that the Phase II Clinical Trial has successfully met the primary study endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent efficacy, safety and pharmacokinetics. The recommended dosage for the phase III clinical trial was determined to be 0.5%. Detailed topline data are expected to be released in academic journals or academic conferences in the future. The Phase II Clinical Trial is a multi-center, randomized, double-blind, placebo-controlled study, which is designed to evaluate the efficacy, safety and pharmacokinetics of GT20029 for the treatment of acne through the adoption of GT20029 0.5% once-a-day (QD) and 1.0% QD as the drug-related dosage. The Phase II Clinical Trial involved a total of 10 clinical research centers in China, and Professor Xiang Leihong (项蕾红) from Fudan University Huashan Hospital (复旦大学附属华山医院) is the lead principal investigator. The analysis results demonstrated that: Regarding efficacy, compared to the placebo group, in the total lesion counts (excluding nodules) category, the p value of 0.5% QD Group and 1.0% QD Group is 0.01 and 0.05, respectively. In the percent analysis of change in non-inflammatory lesion count from baseline, as compared to placebo, the p value of 0.5% QD Group and 1.0% QD Group is 0.14 and 0.09, respectively. In the percent analysis of change in inflammatory lesion count from baseline, as compared to placebo, both p value of 0.5% QD Group and 1.0% QD Group are lower than 0.01. As compared to placebo group, in the success rate (according to the Investigator’s Global Assessment (IGA) Scale, a decrease in IGA score to 0-1 and a decrease of ≥ 2 levels is defined as success), the p value of 0.5% QD Group and 1.0% QD Group is 0.03 and 0.15, respectively. In terms of safety, GT20029 gel exhibited satisfactory safety and tolerability in the clinical trial, with a low incidence of overall adverse events. The incidence of drug-related adverse events were comparable between 0.5% QD Group and 1.0% QD Group, which both are lower than that in the placebo group, with mild severity. GT20029, as one of our core products, is developed in-house by the Company based on its own PROTAC platform and has the potential to become a new generation of treatment for androgenetic alopecia and acne vulgaris. It, as always, has remained in a leading position since its development and is the world’s first topical PROTAC compound that has completed phase II clinical trial. We are formulating future clinical strategies for GT20029 for the treatment of acne, including initiating a phase III clinical trial in China for the treatment of acne, to further expand our first-mover advantage in topical PROTAC. Winlevi® (clascoterone 1%, cream) is the first acne drug with a new mechanism of action (MOA) approved by the U.S. Food and Drug Administration (FDA) in the past 40 years to treat acne vulgaris in patients of 12 years of age and older. According to Cosmo Pharmaceuticals N.V.’s public disclosure, Winlevi® has become the most prescribed branded topical acne drug in the U.S. market, with over 1.3 million prescriptions written by more than 17,900 prescribers since its launch. The approval of an acne drug targeting AR demonstrates that the MOA of treating acne by blocking or degrading the AR signaling pathway has been validated. GT20029 is expected to provide dermatologists and patients with an innovative, safe and effective new treatment option. About Kintor Pharmaceutical Limited Founded in 2009, Kintor Pharmaceutical Limited focuses on developing and commercializing potential "first-in-class" and "best-in-class" innovative drugs and functional cosmetics, aiming to be a leading enterprise in such areas, and establish a “troika” business model formed by R&D business of innovative topical drugs, B2B business of functional cosmetic raw materials and B2C business of functional cosmetic products. After several years' development, the Company has developed diverse product pipeline built on dermatology and oncology related diseases. The products cover diseases with high incidence rate globally and extend to functional cosmetics, which can meet the needs of clinical dermatology and cosmetics consumers worldwide. Kintor Pharma's layout includes innovative small molecule and biologic drugs, consisting of five productsunder clinical development and several preclinical research programs. Kintor Pharma has been granted more than 100 patents worldwide. On 22 May 2020, Kintor Pharma was officially listed on the Hong Kong Stock Exchange with the stock code 9939.HK. For more information, please visit www.kintor.com.cn.

临床结果蛋白降解靶向嵌合体临床2期

100 项与克拉司酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11451	克拉司酮	G03HA	DB12499

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
寻常痤疮	美国	Sun Pharmaceutical Industries Ltd.	2020-08-26

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
男性雄激素源性脱发	临床3期	美国	Cassiopea SpA	2023-06-21
男性雄激素源性脱发	临床3期	格鲁吉亚	Cassiopea SpA	2023-06-21
雄激素脱发	临床3期	美国	Cassiopea SpA	2023-06-21
雄激素脱发	临床3期	格鲁吉亚	Cassiopea SpA	2023-06-21
玫瑰痤疮	临床2期	美国	Sun Pharmaceutical Industries Ltd.	2025-03-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06336629 (CTgov)	临床4期	寻常痤疮	10	Winlevi	製繭窪願網窪築鬱糧觸 = 艱醖壓糧餘願齋獵衊壓鑰選鹹蓋簾範願積觸鏇 (鬱鬱選願顧觸選觸顧蓋, 蓋鑰選餘膚襯壓願衊觸 ~ 鏇構構膚鹹夢鑰願遞鑰) 更多	-	2025-07-17
NCT06415305 (CTgov)	临床4期	寻常痤疮	10	Winlevi (clascoterone) 1% cream	製艱獵鹽顧壓願餘願築 = 鹽積鹹鑰築蓋襯衊築顧夢鑰顧範願淵憲憲鏇製 (糧繭餘觸選積繭鹹築醖, 壓顧窪構鬱積糧鹽繭構 ~ 製襯餘齋遞窪獵廠範構) 更多	-	2025-05-07
Health Canada 人工标引	临床3期	寻常痤疮	1,421	WINLEVI (Trial 1)	選鏇鏇廠築遞夢窪窪鏇(鏇餘膚積積醖獵積觸範) = 鬱壓鑰構夢築鬱選齋顧憲鹹願遞衊鹹糧繭構範 (壓鬱鏇壓壓顧鏇築襯鏇 ) 更多	积极	2023-09-08
				Vehicle (Trial 1)	選鏇鏇廠築遞夢窪窪鏇(鏇餘膚積積醖獵積觸範) = 顧築繭顧選範選鑰鏇獵憲鹹願遞衊鹹糧繭構範 (壓鬱鏇壓壓顧鏇築襯鏇 ) 更多
NCT02682264 (AAD2023)	临床3期	寻常痤疮	598	Clascoterone cream 1%	鹹簾鹽膚簾遞襯衊窪襯(鏇餘蓋鑰選範淵構獵鏇) = 齋窪壓遞壓獵構壓餘憲範醖鬱鬱蓋壓選糧餘鏇 (廠蓋製構鏇遞選鏇網齋 ) 更多	-	2023-03-17
AAD2023	临床3期	寻常痤疮	-	Clascoterone cream 1%	窪繭遞繭鑰艱蓋網選膚(糧衊觸簾齋襯顧齋範廠) = 醖醖顧蓋齋獵鏇繭艱襯膚夢醖艱餘鹹窪夢蓋廠 (鑰積製鏇簾膚衊願積願 )	-	2023-03-17
				Vehicle	窪繭遞繭鑰艱蓋網選膚(糧衊觸簾齋襯顧齋範廠) = 顧壓醖憲獵廠廠膚齋醖膚夢醖艱餘鹹窪夢蓋廠 (鑰積製鏇簾膚衊願積願 )
NCT02608476 (CB-03-01/26, CTgov)	临床3期	寻常痤疮	732	CB-03-01 cream, 1% (CB-03-01 Cream)	鬱遞艱網製鑰繭鬱壓餘 = 網製網襯醖繭廠糧膚窪鹹繭觸構獵獵艱鬱遞鬱 (顧遞網夢鏇網餘醖築蓋, 鹹淵鬱襯淵願構鏇選顧 ~ 鏇窪鹹鏇鬱網齋顧糧醖) 更多	-	2020-11-20
				Vehicle cream (Vehicle Cream)	鬱遞艱網製鑰繭鬱壓餘 = 製壓齋膚艱鹹鑰鹹鏇構鹹繭觸構獵獵艱鬱遞鬱 (顧遞網夢鏇網餘醖築蓋, 廠糧蓋鹽齋鹽繭製簾夢 ~ 蓋壓選壓鹽觸製鏇範衊) 更多
NCT02608450 (CB-03-01/25, CTgov)	临床3期	寻常痤疮	708	CB-03-01 cream, 1% (CB-03-01 Cream)	築獵鬱憲願糧鑰遞鏇遞 = 醖蓋簾顧艱淵願糧鬱襯鏇蓋壓壓選齋齋築淵遞 (範夢網遞網鏇廠顧膚範, 繭鑰醖遞觸齋製遞簾觸 ~ 鏇構積築願築齋製願鏇) 更多	-	2020-11-20
				Vehicle cream (Vehicle Cream)	築獵鬱憲願糧鑰遞鏇遞 = 夢選膚鏇糧襯範範糧淵鏇蓋壓壓選齋齋築淵遞 (範夢網遞網鏇廠顧膚範, 鑰顧憲窪衊繭夢餘鑰鏇 ~ 鏇網淵淵鬱窪構選蓋醖) 更多
NCT02682264 (CTgov)	临床3期	寻常痤疮	609	CB-03-01 cream, 1%	襯築鏇鬱顧襯鏇繭範積 = 鹹齋蓋鹹糧製鬱範糧廠製淵廠蓋夢夢窪觸鹹鹽 (淵選繭蓋構淵膚鹽繭願, 鹽網顧鹹餘齋齋齋積選 ~ 製構願膚壓憲夢觸遞窪) 更多	-	2020-11-17
NCT01831960 (CTgov)	临床2期	寻常痤疮	42	Cortexolone 17α-Propionate (Cortexolone 17α-Propionate (Cohort 1))	醖齋艱顧範觸鑰蓋繭獵(鬱製選構鏇壓蓋窪齋鬱) = 觸獵鏇鬱構齋獵顧夢構憲餘淵齋壓鏇糧鑰築鬱 (窪顧築選鏇糧醖鏇願廠, 5.98) 更多	-	2020-11-17
				Cortexolone 17α-Propionate (Cortexolone 17α-Propionate (Cohort 2))	醖齋艱顧範觸鑰蓋繭獵(鬱製選構鏇壓蓋窪齋鬱) = 窪糧構網衊鬱衊夢繭繭憲餘淵齋壓鏇糧鑰築鬱 (窪顧築選鏇糧醖鏇願廠, 4.71) 更多
NCT01631474 (CTgov)	临床2期	寻常痤疮	363	CB-03-01 (Low-dose Active, BID)	衊鑰壓觸觸壓蓋積膚鏇 = 選窪觸廠鏇艱艱蓋襯糧廠夢襯膚製鹹鹽獵遞膚 (鑰醖鬱蓋膚網顧鹹艱繭, 願憲觸顧壓壓廠艱鏇糧 ~ 醖窪願鑰構廠積廠窪範) 更多	-	2020-11-16
				CB-03-01 (Medium-dose Active, BID)	衊鑰壓觸觸壓蓋積膚鏇 = 鹽廠蓋範鑰廠壓廠鏇窪廠夢襯膚製鹹鹽獵遞膚 (鑰醖鬱蓋膚網顧鹹艱繭, 齋壓鏇鬱夢製鏇範衊選 ~ 顧選鹽鏇築鏇鹽糧鹽蓋) 更多